Abstract 897P
Background
The early response to concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (LA-NPC) is closely correlated with prognosis. In this study, we aimed to predict early response using a combined model that combines sub-regional radiomics features from multi-sequence MRI with clinically relevant factors.
Methods
A total of 104 patients with LA-NPC were randomly divided into training and validation cohorts at a ratio of 3:1. Radiomic features were extracted from subregions within the tumor area using the K-means clustering method, and feature selection was performed using LASSO regression. Four models were established: classical radiomics model, clinical medol, Intratumor Heterogeneity (ITH) score-based model and a fusion model combining ITH score with clinical factors. The predictive performance of these models was evaluated using receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA).
Results
Among the models, the combined model incorporating ITH score and clinical factors demonstrated the highest predictive performance in the test cohort (AUC = 0.838). Additionally, the models based on ITH score showed superior prognostic value in both the training cohort (AUC = 0.888) and the test cohort (AUC = 0.833).
Conclusions
The combined model that integrates the ITH score with clinical factors exhibited superior performance in predicting early response following concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma.
Clinical trial identification
Editorial acknowledgement
The authors would like to thank Yuandong Cao, Weilin Xu, and Shu Zhou for their valuable comments and discussions. We also express their gratitude to Jinling Yuan and Mengxing Wu for their assistance with data analysis. This work was supported by the Jiangsu Province Doctoral Start-up Foundation for Entrepreneurship and Innovation (Grant No. 2019303073386ER19) and the Clinical Competence Enhancement Project of Jiangsu Provincial People's Hospital (Grant No. JSPH-MC-2021-17).
Legal entity responsible for the study
The First Affiliated Hospital of Nanjing Medical University.
Funding
Jiangsu Province Entrepreneurship and Innovation Doctoral Talent Program.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
900P - Notch inhibitor AL101 prior to surgery in patients (pts) with Notch1 activated adenoid cystic carcinoma (ACC): Safety and efficacy in a window of opportunity study
Presenter: Renata Ferrarotto
Session: Poster session 02
901P - A phase II trial of neoadjuvant nivolumab, docetaxel, and cisplatin therapy followed by surgery and radiation therapy for resectable high-grade salivary gland carcinoma
Presenter: Sehhoon Park
Session: Poster session 02
902P - Comparison of progression free and overall survival (OS) with bicalutamide and 4-weekly or 12-weekly triptorelin in androgen receptor positive (AR+) salivary gland cancer (SGC)
Presenter: Amelia Handley
Session: Poster session 02
903P - Patterns and predictors of recurrence-free survival (RFS) in salivary gland cancers (SGCs): A Spanish multicenter study
Presenter: Alexandre Izquierdo Miranda
Session: Poster session 02
904P - Analysis of TP63 immunohistochemistry scores (IHC) by primary site and between primary and metastatic tumours in adenoid cystic carcinoma (ACC)
Presenter: Laura Spurgeon
Session: Poster session 02
905P - Validation of MYC/TP63 classification for adenocystic carcinomas of salivary glands
Presenter: Panagiota Economopoulou
Session: Poster session 02
906P - Prognostic impact and therapeutic implications of comprehensive genomic profiling (CGP) in non-metastatic salivary gland cancers (nmSGC)
Presenter: Mario Balsa Pena
Session: Poster session 02